Monday Apr 7
Positive Results Reported for Palbociclib Plus Letrozole in Patients With Advanced Breast Cancer
Positive results have been reported from the PALOMA-1 trial, a randomized phase II study of palbociclib in combination with the aromatase inhibitor letrozole .
Pfizer drug doubles time to breast cancer tumor growth in trial
Pfizer Inc's experimental breast cancer drug in a clinical trial nearly doubled the amount of time patients lived without their disease getting worse, but overall survival was not yet shown to be statistically significant, researchers said.
The Motley Fool
Is Novartis' Strategy a Winning One?
Indeed, over the period, net profit has increased from $8.2 billion in 2008 During that time the company, under the leadership of Daniel Vasella, diversified its operations to include vaccines and generic drugs.